npm alk (Cell Signaling Technology Inc)
Cell Signaling Technology Inc is a verified supplier 
Cell Signaling Technology Inc manufactures this product 
96
Structured Review
Cell Signaling Technology Inc
npm alk
Npm Alk, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 215 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/npm alk/product/Cell Signaling Technology Inc
Average 96 stars, based on 215 article reviews
Npm Alk, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 215 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/npm alk/product/Cell Signaling Technology Inc
Average 96 stars, based on 215 article reviews
npm alk - by Bioz Stars,
2026-03
96/100 stars
Images
1) Product Images from "ALK-transformed mature T lymphocytes restore early thymus progenitor features"
Article Title: ALK-transformed mature T lymphocytes restore early thymus progenitor features
Journal: The Journal of Clinical Investigation
doi: 10.1172/JCI134990
Figure Legend Snippet: (A) Expression by qRT-PCR analysis of NPM-ALK mRNA in the transformed CD4+ T cells (CD4-NPM/ALK+ lane shows the mean from 9 independent cell lines) and 3 positive control NPM-ALK+ ALCL cell lines: KARPAS-299, SU-DHL-1, and COST.CD4+ T cells preactivated with CD3/CD28 antibody-coated beads were used as negative controls (preactivated CD4). MLNS1 was used as an internal control. Relative NPM-ALK expression was expressed as the 2–ΔCt relative to MLN51. Data represent mean ± SEM. *P < 0.05, **P < 0.001, ***P < 0.001; unpaired 2-tailed Student’s t test with Welch’s correction. (B) Suppressive effect of the ALK inhibitor crizotinib (500 nmol/L) on ALK and STAT3 phosphorylation in transformed CD4+ T cells and control NPM-ALK+ KARPAS-299 cells. The GAPDH protein served as an internal control to ensure equal loading. Blots from 1 representative experiment are shown.
Techniques Used: Expressing, Quantitative RT-PCR, Transformation Assay, Positive Control, Control, Phospho-proteomics
Figure Legend Snippet: Normal CD4+ T cells prestimulated with CD3/CD28 antibody-coated beads were transduced with NPM-ALK and 40 days later flow cytometry analysis was performed to detect expression of T cell markers stained with an anti-ALK, -CD3, -CD4, -CD30, and -TCRαβ antibodies (NPM-ALK+ CD4+ T cells in green and prestimulated healthy CD4+ T cells in red) or IgG as control (blue). Preactivated human healthy CD4+ T cells were used as controls. Data are representative of the mean ± SEM from the 9 independent cell lines.
Techniques Used: Transduction, Flow Cytometry, Expressing, Staining, Control
Figure Legend Snippet: (A) NPM-ALK–transformed CD4+ T cells were injected subcutaneously into the left or right flank of NSG mice (n = 2). Representative image of tumor-bearing mice. (B) Tumor volume was evaluated over time by caliper measurements and reported as mean ± SEM (line). (C) Representative images of H&E staining and immunohistochemical staining for expression of NPM-ALK, CD3, CD4, and CD30 (original magnification ×20 or ×40; inset ×80).
Techniques Used: Transformation Assay, Injection, Staining, Immunohistochemical staining, Expressing
Figure Legend Snippet: Experimental metastasis assays were performed in NSG mice using NPM-ALK–transformed CD4+ T cells (n = 7) or PBS (n = 3) with injection through the mouse tail vein. (A) Representative image of cutaneous metastasis-bearing mice. Metastatic burden was assessed at 39 days after injection. (B–I) Representative H&E images. Mice presented skin nodules without dermis and subcutis hyperplasia (A–C) and spleen hyperplasia (D). A lymphomatous infiltration invaded the liver (E) and spleen (F). The neoplastic cells included a predominant population of small- to medium-sized neoplastic cells with irregular nuclei (G). Many cells are fried-egg cells with pale cytoplasms and centrally located nuclei (H, arrowheads) and cells with ring-like nuclei (I, arrowheads). Histological analysis with anti-ALK antibody showed a strong ALK staining in the large lymphoma cells as compared with the small variants (J and K). Small cells are often localized around blood vessels (L). Original magnifications ×5, ×20, or ×40).
Techniques Used: Transformation Assay, Injection, Staining
![(A) We used publicly available methylation data sets (30) generated from different developmental T cell stages (multipotent ETPs [CD34+/CD1a–; n = 2]; T cell–committed progenitors [CD34+/CD1a+; n = 1]; pre-TCR T cells [n = 2]; TCR-expressing CD4+/CD8+ double-positive T cells [DP-TCR+, n = 2]; and single positive [SP] CD8+ or CD4+ cells [SP-CD4+; n = 2 or SP-CD8+; n = 2]) to identify a cluster of 510 DMRs available to discriminate each different stage of T cell differentiation in the thymus. (B) Hierarchical clustering dendrogram using a cluster of 510 DMRs revealed that NPM-ALK–transformed CD4+ T cells were distant to the healthy CD4+ lymphocyte profile and clustered with primary NPM-ALK+ ALCL biopsies. Heatmaps also showed a similarity of NPM-ALK+ cells (NPM-ALK–transformed CD4+ T cells and primary patient–derived NPM-ALK+ ALCL) with CD34+/CD1a– cells corresponding to the ETP stage.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_5726/pmc07685726/pmc07685726__jci-130-134990-g167.jpg "... using a cluster of 510 DMRs revealed that NPM-ALK–transformed CD4+ T cells were distant to the healthy ...")
Figure Legend Snippet: (A) We used publicly available methylation data sets (30) generated from different developmental T cell stages (multipotent ETPs [CD34+/CD1a–; n = 2]; T cell–committed progenitors [CD34+/CD1a+; n = 1]; pre-TCR T cells [n = 2]; TCR-expressing CD4+/CD8+ double-positive T cells [DP-TCR+, n = 2]; and single positive [SP] CD8+ or CD4+ cells [SP-CD4+; n = 2 or SP-CD8+; n = 2]) to identify a cluster of 510 DMRs available to discriminate each different stage of T cell differentiation in the thymus. (B) Hierarchical clustering dendrogram using a cluster of 510 DMRs revealed that NPM-ALK–transformed CD4+ T cells were distant to the healthy CD4+ lymphocyte profile and clustered with primary NPM-ALK+ ALCL biopsies. Heatmaps also showed a similarity of NPM-ALK+ cells (NPM-ALK–transformed CD4+ T cells and primary patient–derived NPM-ALK+ ALCL) with CD34+/CD1a– cells corresponding to the ETP stage.
Techniques Used: Methylation, Generated, Expressing, Cell Differentiation, Transformation Assay, Derivative Assay
Figure Legend Snippet: Two hundred and forty-three among the 510 DMRs within NPM-ALK–transformed CD4+ T cells (CD4+/NPM-ALK+), primary patient–derived NPM-ALK+ ALCL cells, and CD34+/CD1a– cells corresponding to the ETP stage. Venn diagram reveals that the ETP and both the NPM-ALK+ tumor cell entities (CD4+/NPM-ALK+ lymphoma cells and primary NPM-ALK+ ALCLs) share 38 DMRs with similar expression patterns.
Techniques Used: Transformation Assay, Derivative Assay, Expressing
Figure Legend Snippet: mRNA expression profiles from several cell populations isolated ex vivo from the neonatal human thymus defining in vivo maturation stages, multipotent ETPs (CD34+/CD1a–/CD7–; n = 3), late thymic precursor (CD34+/CD1a–/CD7+; n = 3), T cell–committed progenitors (CD34+/CD1a–/CD7+; n = 3), CD3–/CD4+ immature single-positive (ISP) (ISP-CD4+, n = 4), CD4+/CD8+ double-positive TCR– cells (DP-TCR–; n = 3), and TCR-expressing CD4+/CD8+ double-positive T cells (DP-TCR+, n = 3) were integrated with our previous findings from the gene expression array data of 55 primary NPM-ALK+ ALCL samples (NPM-ALK+ ALCL) (35) and RNA-Seq data from the NPM-ALK–transformed CD4+ T cells (CD4+/NPM-ALK+; n = 9). NPM-ALK CD4+/NPM-ALK+ cells were distant to the healthy CD4+ lymphocyte but close to NPM-ALK+ ALCL. Moreover, NPM-ALK+ cells (NPM-ALK–transformed CD4+ T cells and primary patient–derived NPM-ALK+ ALCL) showed a similarity with the ETP stage.
Techniques Used: Expressing, Isolation, Ex Vivo, In Vivo, Gene Expression, RNA Sequencing, Transformation Assay, Derivative Assay
Figure Legend Snippet: (A) Quantitative RT-PCR analysis of ALK and EPAS1 mRNA was performed in primary patient–derived NPM-ALK+ ALCL cells (n = 29). Relative mRNA expression was expressed as the 2–ΔΔCt relative to MLN51, S5, ABL, GAPDH, S14, or RPL0 genes for normalization and compared with preactivated healthy CD4+ lymphocytes (n = 5). Data represent mean ± SEM. ***P < 0.001; unpaired 2-tailed Student’s t test. (B) Quantitative RT-PCR analysis of EPAS1 mRNA expression in NPM-ALK+ lymphoma cell lines, COST, KARPAS-299 (KARPAS), and SU-DHL1, treated for 72 hours or not (PBS) with crizotinib or transfected with either an irrelevant siRNA as the negative control (si-CTL) or a siRNA targeting ALK mRNA (si-ALK) or STAT3 (si-STAT3). Relative EPAS1 mRNA expression was expressed as the 2–ΔCt relative to MLN51. Data represent mean ± SEM from 3 independent experiments. *P < 0.05, ***P < 0.001; unpaired 2-tailed Student’s t test with Welch’s correction. (C) Western blotting analysis of HIF2A expression (top) in NPM-ALK+ COST, KARPAS-299, and SU-DHL1 cells treated with crizotinib (crizo) or not (PBS), transfected by si-CTL, si-ALK, or si-STAT3. The GAPDH protein (bottom) served as an internal control to ensure equal loading. Results from 1 representative experiment are shown.
Techniques Used: Quantitative RT-PCR, Derivative Assay, Expressing, Transfection, Negative Control, Western Blot, Control